Could a cheaper copy of a key chemo drug work just as well?

NCT ID NCT07648940

Completed Disease control Sponsor: Zodiac Produtos Farmaceuticos S.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new formulation of the chemotherapy drug doxorubicin (Doxopeg) to the standard version (Caelyx) in people with advanced ovarian cancer or metastatic breast cancer. The goal is to see if the two drugs are absorbed and processed by the body in the same way. Participants receive a single dose of each drug in a random order, and blood samples are taken over two weeks to measure drug levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pegylated liposomal doxorubicin (Doxopeg, Caelyx)
What this could lead to: If the new formulation is shown to be equivalent, it could offer a more affordable or accessible treatment option for advanced ovarian and breast cancers.
What could go wrong: This is an early-phase bioequivalence study, not a test of effectiveness. The new drug may not match the reference drug in real-world use, and side effects like heart damage or hand-foot syndrome remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OVARIAN CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

Adium S.A.

São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.